CD34 stem cell-related methods and compositions
First Claim
Patent Images
1. A method for treating a subject afflicted with a tumor comprising introducing into the subject'"'"'s bloodstream a therapeutically effective number of genetically modified CD34−
- stem cells, wherein (a) each of the genetically modified CD34−
stem cells contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified CD34−
stem cells come into proximity with, and differentiate into endothelial-like cells in proximity with, tumor tissue undergoing angiogenesis, directly and/or indirectly causing tumor tissue death, and (b) the introduction of the genetically modified CD34−
stem cells is not preceded, accompanied or followed by myeloablation.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34− stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34− stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
-
Citations
7 Claims
-
1. A method for treating a subject afflicted with a tumor comprising introducing into the subject'"'"'s bloodstream a therapeutically effective number of genetically modified CD34−
- stem cells, wherein (a) each of the genetically modified CD34−
stem cells contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified CD34−
stem cells come into proximity with, and differentiate into endothelial-like cells in proximity with, tumor tissue undergoing angiogenesis, directly and/or indirectly causing tumor tissue death, and (b) the introduction of the genetically modified CD34−
stem cells is not preceded, accompanied or followed by myeloablation. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- stem cells, wherein (a) each of the genetically modified CD34−
Specification